Breaking News Instant updates and real-time market news.

MDT

Medtronic

$85.85

-0.83 (-0.96%)

, CSCO

Cisco

$44.02

0.09 (0.20%)

09:08
06/14/18
06/14
09:08
06/14/18
09:08

Piper Jaffray to hold a summit

Heartland Summit will be held in Minneapolis on June 14.

MDT

Medtronic

$85.85

-0.83 (-0.96%)

CSCO

Cisco

$44.02

0.09 (0.20%)

UNH

UnitedHealth

$252.90

-0.64 (-0.25%)

RMD

ResMed

$106.78

-0.14 (-0.13%)

FIT

Fitbit

$7.39

-0.19 (-2.51%)

LLY

Eli Lilly

$85.70

0.21 (0.25%)

BDX

Becton Dickinson

$232.22

-1.61 (-0.69%)

LH

LabCorp

$187.71

-1.23 (-0.65%)

GSK

GlaxoSmithKline

$41.15

-0.065 (-0.16%)

JNJ

Johnson & Johnson

$122.65

0.11 (0.09%)

DGX

Quest Diagnostics

$110.63

-0.37 (-0.33%)

MMM

3M

$204.89

-0.04 (-0.02%)

AMGN

Amgen

$183.64

-1.47 (-0.79%)

MCK

McKesson

$149.42

3.85 (2.64%)

BAX

Baxter

$74.57

-0.825 (-1.09%)

XRAY

Dentsply Sirona

$44.50

0.31 (0.70%)

  • 14

    Jun

  • 14

    Jun

  • 14

    Jun

  • 14

    Jun

  • 18

    Jun

  • 19

    Jun

  • 19

    Jun

  • 20

    Jun

  • 25

    Jun

  • 26

    Jun

  • 28

    Jun

  • 10

    Jul

  • 12

    Jul

  • 12

    Jul

  • 17

    Jul

  • 25

    Jul

  • 10

    Sep

  • 27

    Sep

MDT Medtronic
$85.85

-0.83 (-0.96%)

06/06/18
PIPR
06/06/18
NO CHANGE
Target $96
PIPR
Overweight
Piper likes setup for Medtronic shares after yesterday's pullback
Piper Jaffray analyst Matt O'Brien attributes yesterday's pullback in shares of Medtronic to management offering conservative guidance at the investor meeting and delaying the timing for the company's much anticipated surgical robotic system to fiscal 2020. Medtronic has a "ton of needle-moving new technologies in development," O'Brien tells investors in a research note. The analyst is confident in a "strong top-line in the coming years" and likes the setup for Medtronic shares after yesterday's selloff. He keeps an Overweight rating on the stock with a $96 price target.
06/06/18
WBLR
06/06/18
INITIATION
WBLR
Market Perform
Medtronic assumed with a Market Perform at William Blair
William Blair analyst Margaret Kaczor assumed coverage of Medtronic with a Market Perform rating. The analyst believes it will be difficult for the company to grow sales above 4% without the help of acquisitions.
06/11/18
PIPR
06/11/18
NO CHANGE
Target $32.5
PIPR
Overweight
Piper doesn't see regulatory issues for possible Stryker, Boston Scientific deal
Piper Jaffray analyst Matt O'Brien believes regulatory constraints from Stryker's (SYK) potential acquisition of Boston Scientific (BSX) "should not be much of an issue" given the little overlap between the businesses. The deal structure would be the biggest issue facing Stryker as the company would likely have to lever up heavily to acquire Boston Scientific, O'Brien tells investors in a research note. The analyst believes a transaction could occur in the $52B-$54B range, assuming a typical medtech takeout premium of 20%-30%. Consequently, any transaction would either require a significant level of debt or dilution to Stryker shareholders, the analyst contends. He sees the potential deal as likely being dilutive until 2021. O'Brien has an Overweight rating on Boston Scientific with a $32.50 price target. The stock closed the trading day up 7% to $34.32 after the Wall Street Journal reported that Stryker approached the company regarding a takeover.
06/06/18
NEED
06/06/18
NO CHANGE
Target $103
NEED
Buy
Medtronic's financial targets 'achievable,' says Needham
Needham analyst Mike Matson raised his price target for Medtronic to $103 from $97 and reiterated a Buy rating following the company's investor day in New York City, which he says increased his confidence in the company's product portfolio and that its new financial targets, including organic revenue growth for FY18-FY22 of 4%+, adjusted EPS growth of 8%+ and operating margin expansion of 40-50bps per year, are "realistic" and "achievable."
CSCO Cisco
$44.02

0.09 (0.20%)

05/17/18
RBCM
05/17/18
NO CHANGE
Target $50
RBCM
Outperform
Cisco post-earnings stock dip is a buying opportunity, says RBC Capital
RBC Capital analyst Mitch Steves kept his Outperform rating and $50 price target on Cisco, saying the slight pullback in the stock price following the in-line earnings and guidance may be a buying opportunity. The analyst cites continued growth in deferred revenues while also forecasting growth in Switching sales for 2-3 quarters given the backlog and its high margin levels. Steves also notes Cisco's history of buybacks when its stock price traded in $42-$44 per share range, creating a "nice support for the stock".
06/04/18
COWN
06/04/18
NO CHANGE
Target $51
COWN
Outperform
Cisco cloud opportunity outweighs risk, says Cowen
Cowen analyst Paul Silverstein said Cisco management made a case that the emergence of Public Clouds, specifically the migration toward a Multi-Cloud IT world, presents the company with greater opportunity than risk. He said the case calls for revenue opportunities from both Public Cloud Operators and Enterprises as growth drivers. Silverstein reiterated his Outperform rating and $51 price target on Cisco shares.
05/17/18
MSCO
05/17/18
NO CHANGE
Target $50
MSCO
Overweight
Cisco laying groundwork for upside in FY19, says Morgan Stanley
Following Cisco's report of "strong" Q3 results and "generally positive" comments from management regarding the outlook, Morgan Stanley analyst James Faucette said the earnings call "offered ample evidence" Cisco's software strategy is progressing well. He sees software helping to stabilize equipment replacement cycles and believes the stock will approach $50 as the market becomes more convinced FY19 estimates are too low. Faucette maintains an Overweight rating and $50 price target on Cisco shares.
05/18/18
ARGS
05/18/18
NO CHANGE
Target $55
ARGS
Buy
Cisco price target raised to $55 from $50 at Argus
Argus analyst Jim Kelleher raised his price target on Cisco to $55 and kept his Buy rating after its Q3 results, saying the pullback in the stock price despite the above or in-line earnings and guidance suggests that investors were looking to take profits following a 30% run-up over the past year. Kelleher notes "good momentum" in the company's largest category - Enterprise - where orders were up in low double digits. The analyst also sees "multiple positives" in Cisco's outlook, such as rapid growth in CAT 9000, greater contribution from recurring revenue, and capital return potential from "exceptional" cash flows.
UNH UnitedHealth
$252.90

-0.64 (-0.25%)

06/08/18
WBLR
06/08/18
UPGRADE
WBLR
Outperform
William Blair upgrades Quest Diagnostics to Outperform on secular tailwinds
William Blair analyst Amanda Murphy upgraded Quest Diagnostics (DGX) to Outperform from Market Perform citing the recent UnitedHealthcare (UNH) contract change and positive secular trends for larger labs. The analyst believes both LabCorp (LH) and Quest should benefit from secular tailwinds. We are in the early innings of a cycle of lab market share shift from hospital labs to independent labs, Murphy tells investors in a research note. She finds it hard to argue that the new it is hard to argue that the new UnitedHealthcare contract is not good for Quest.
06/07/18
06/07/18
UPGRADE
Target $210

Overweight
LabCorp upgraded to Overweight at KeyBanc
As previously reported, KeyBanc analyst Donald Hooker upgraded LabCorp (LH) to Overweight from Sector Weight, with a $210 price target. The analyst sees LabCorp and Quest Diagnostics (DGX) benefiting over time from their recent contracts with United Healthcare (UNH) and Aetna (AET). Between LabCorp and Quest Diagnostics, Hooker sees the former as having the more timely valuation.
06/12/18
PIPR
06/12/18
NO CHANGE
Target $116
PIPR
Overweight
DexCom price target raised to $116 from $93 at Piper Jaffray
Piper Jaffray analyst JP McKim raised his price target for DexCom to $116 citing two new data points and his consumer continuous glucose monitoring survey. The first data point, that Centers for Medicare & Medicaid Services will now allow Medicare patients to use their smart phone with CGM including the share function is a slight positive for DexCom, McKim tells investors in a research note. The second data point, which is the analyst was not able to confirm, is UnitedHealth (UNH) maybe moving to a bundled payment for CGM. And thirdly, McKim says his May consumer survey confirms a continued shift to CGM with more Type 2s is coming into the market. He believes DexCom remains the best way to play this trend and that the G6 launch will be a "meaningful driver of growth." The analyst keeps an Overweight rating on the shares
06/07/18
BMOC
06/07/18
NO CHANGE
Target $285
BMOC
Outperform
UnitedHealth's dividend announcement 'incrementally positive signal,' says BMO
BMO Capital analyst Matt Borsch raised his price target for UnitedHealth to $285 from $275 and reiterated an Outperform rating for the shares following the company's announcement that it will raise its quarterly dividend 20% and increase its share repurchase authorization to 100M shares. While Borsch says this was not a directional surprise, he views the announcement nonetheless as an incrementally positive signal on the near-term outlook.
RMD ResMed
$106.78

-0.14 (-0.13%)

04/04/18
04/04/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. PTC Therapeutics (PTCT) downgraded to Underweight from Equal Weight at Barclays with analyst Gena Wang saying she sees limited upside to 2018 revenue expectations and believes PTC's growth trajectory is fully priced in at current valuation levels. 2. Cloudera (CLDR) downgraded to Neutral from Overweight at JPMorgan and to Hold from Buy at Deutsche Bank. 3. Domino's Pizza (DPZ) downgraded to Hold from Buy at Deutsche Bank with analyst Brett Levy citing valuation. 4. Virtusa (VRTU) downgraded to Hold from Buy at SunTrust with analyst Frank Atkins saying while Virtusa stock has risen 166% since November of 2016, future upside may be more limited. 5. ResMed (RMD) downgraded to Neutral from Buy at Citi with analyst Victor Windeyer citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, Reference Link
04/23/18
UBSW
04/23/18
DOWNGRADE
UBSW
Neutral
ResMed downgraded to Neutral from Buy at UBS
05/31/18
05/31/18
NO CHANGE

Arcturus Therapeutics reinstates founder Joseph Payne as CEO
Arcturus Therapeutics (ARCT) has named Dr. Peter Farrell as Chairman of the Board of Directors of the company. Joseph E. Payne has been reinstated as President and CEO and Dr. Pad Chivukula has been reinstated as Chief Scientific Officer and COO. Peter Farrell is the founder, former long-term CEO and current Chairman of ResMed (RMD).
05/30/18
PIPR
05/30/18
NO CHANGE
Target $190
PIPR
Overweight
Inogen recent pullback a buying opportunity, says Piper Jaffray
Piper Jaffray analyst JP McKim views the recent pullback in shares of Inogen (INGN) as unwarranted and recommends buying the shares at current levels. The analyst says his firm's survey of 66 home medical equipment providers indicates the shift to portable oxygen concentrators "remains strong." The market remains in the early innings of this conversion and Inogen is the best way to play this thematic trend, McKim tells investors in a research note. The analyst expects ResMed's (RMD) Mobi to launch this year, but does not expect it to be overly impactful to Inogen. Consensus numbers already reflect a deceleration in growth in the second half of 2018 which is unlikely to materialize, McKim contends. He keeps an Overweight rating on Inogen with a $190 price target.
FIT Fitbit
$7.39

-0.19 (-2.51%)

06/07/18
DADA
06/07/18
NO CHANGE
Target $5.5
DADA
Neutral
Fitbit CFO transition not a concern, says DA Davidson
DA Davidson analyst Tom Forte says he's not concerned by the CFO transition at Fitbit. The analyst has a Neutral rating on the shares with a $5.50 price target. Forte is confident that Fitbit's incoming CFO will be able to contribute to the company's overriding strategy of transforming its business model to a combination of one-time and recurring revenue. He reiterates that signs of improving business fundamentals may inspire him to reconsider his Neutral rating on the shares.
06/07/18
WEDB
06/07/18
NO CHANGE
Target $6
WEDB
Neutral
Fitbit management change not likely to disrupt transition, says Wedbush
Wedbush analyst Alicia Reese does not expect Fitbit CFO Bill Zarella's departure "to create waves." The analyst thinks it was a good choice on the part of management to clearly state in its press release that Zarella is leaving to join an autonomous vehicle startup, indicating that there were no internal issues driving his departure. Fitbit is promoting its Chief Accounting Officer, Ron Kisling, to Chief Financial Officer, Reese notes, adding that she expects the transition to be smooth. The analyst reiterates a Neutral rating and $6 price target on the shares.
06/07/18
MSCO
06/07/18
NO CHANGE
Target $4
MSCO
Underweight
Morgan Stanley says decline in older products still central issue for Fitbit
Morgan Stanley analyst Yuuji Anderson said his recent checks indicate early performance for Fitbit's new Versa smartwatch could be running ahead of near-term expectations. However, he thinks his below consensus FY18 estimates are already giving adequate credit for strong Versa performance and that the market is too optimistic on the time it will take for Fitbit to reach revenue stabilization as his checks also continue to show accelerated declines in older products. Anderson maintains his Underweight rating and $4 price target on Fitbit shares.
05/01/18
ROTH
05/01/18
NO CHANGE
Target $8
ROTH
Buy
Google provides validation to Fitbit digital therapeutics thesis, says Roth Capital
Roth Capital analyst Scott Searle notes that Fitbit (FIT) announced a Google (GOOG; GOOGL) relationship that begins with costs and scale and extends to collaboration and innovation around wearables and its resulting data. The analyst believes Google adds performance and efficiencies as well validates Fitbit's emerging digital therapeutics presence. Searle reiterates a Buy rating and $8 price target on Fitbit's shares.
LLY Eli Lilly
$85.70

0.21 (0.25%)

06/13/18
MSCO
06/13/18
NO CHANGE
MSCO
HHS 'smoke signals' worth noting for drugmakers, says Morgan Stanley
After HHS Secretary Alex Azar spoke at a two-hour Senate hearing, Morgan Stanley analyst David Risinger noted that Azar suggested that U.S. drug pricing needs to move to a system without rebates and said payments from drugmakers to PBMs should be eliminated. In listing four HHS actions that could hurt manufacturers, Risinger pointed out that Azar said he is interested in removing 100% cap on Medicaid rebates; he would like to adjust the Part D protected drug classes so that plans can extract rebates from manufacturers; HHS wants to require manufacturers to disclose drug list prices in TV ads; and HHS is focused on transitioning Part B to lower-priced private sector management. In summary, the analyst said that for drugmakers there was "no fire, but smoke signals worth noting." Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
06/11/18
WELS
06/11/18
NO CHANGE
Target $240
WELS
Outperform
Allergan migraine data on lower end of relative efficiency, says Wells Fargo
Wells Fargo analyst David Maris says his initial review suggests Allergan's (AGN) atogepant's Phase IIb data are "relatively in-line but on the lower end of the efficacy" demonstrated by the calcitonin gene-related peptide migraine treatments in Phase III trials. Atogepant is expected to face competition from Amgen (AMGN)/Novartis (NVS), Eli Lilly (LLY) and Teva (TEVA), which are all developing injectable anti-CGRP treatments, as well as Alder Biopharmaceuticals (ALDR), which has an infusion-administered anti-CGRP in development, Maris tells investors in a research note. He notes that while Allergan will be following these competitors to the market, atogepant will be differentiated in that it is the only oral prophylactic anti-CGRP therapy. The analyst forecasts $75M in sales for atogepant in 2022. He does not believe many investors are giving Allergan credit for atogepant, meaning the "risk to the downside looks limited." Maris keeps an Outperform rating on Allergan shares.
06/13/18
JEFF
06/13/18
DOWNGRADE
Target $50
JEFF
Hold
Armo BioSciences downgraded to Hold from Buy at Jefferies
Jefferies analyst Biren Amin downgraded Armo BioSciences (ARMO) to Hold and lowered his price target for the shares to $50 from $61. The analyst expects the takeover by Eli Lilly (LLY) to close in a few weeks and does not expect a competing bid to emerge.
06/11/18
JPMS
06/11/18
NO CHANGE
Target $100
JPMS
Overweight
Eli Lilly setup attractive with potential upside to estimates, says JPMorgan
JPMorgan analyst Chris Schott views Eli Lilly as one of the best positioned names in his coverage group given his expectations for "continued healthy growth" from core products Trulicity, Jardiance and Taltz, coupled with its late stage pipeline assets and a "significant" margin expansion opportunity. He believes concerns surrounding the diabetes competitive landscape "appear well reflected/overdone" and sees "healthy" GLP-1 category growth driving Trulicity sales over the next five years. Schott reiterates an Overweight rating on Eli Lilly with a $100 price target. The analyst sees an attractive setup for the shares with the potential for near and longer-term upside to estimates.
BDX Becton Dickinson
$232.22

-1.61 (-0.69%)

03/06/18
03/06/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Becton Dickinson (BDX) initiated with a Market Perform at BMO Capital. 2. Cardlytics (CDLX) initiated with a Buy at SunTrust, an Overweight at JPMorgan and KeyBanc, a Neutral at BofA/Merrill, and an Outperform at Wells Fargo. 3. iRhythm (IRTC) initiated with an Outperform at BMO Capital. 4. Genocea (GNCA) initiated with an Overweight at Cantor Fitzgerald. 5. Domino's Pizza (DPZ) initiated with an Outperform at Baird. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/10/18
SBSH
04/10/18
UPGRADE
Target $251
SBSH
Buy
Becton Dickinson upgraded to Buy from Neutral at Citi
Citi analyst Amit Hazan upgraded Becton Dickinson to Buy and raised his price target for the shares to $251 from $237. The analyst sees a "strong setup" for upside to estimates in fiscal 2018, largely driven by the Becton Dickinson side of the business. Further, he sees drug-coated balloons as an important growth driver for the Bard side of the business.
04/10/18
04/10/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Ulta Beauty (ULTA) upgraded to Overweight from Neutral at Piper Jaffray with analyst Erinn Murphy citing Piper's 35th semi-annual teens survey in which Ulta Beauty overtook Sephora as the top brand for average-income teens. 2. Nvidia (NVDA) and Seagate (STX) were upgraded to Overweight from Equal Weight at Morgan Stanley. 3. Live Nation (LYV) upgraded to Buy from Neutral at Citi with analyst Jason Bazinet saying the stock has sold off after the New York Times reported that the Department of Justice is investigating the company for antitrust violations. 4. Becton Dickinson (BDX) upgraded to Buy from Neutral at Citi with analyst Amit Hazan saying he sees a "strong setup" for upside to estimates in fiscal 2018, largely driven by the Becton Dickinson side of the business. 5. Illinois Tool Works (ITW) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Joe Ritchie saying the pullback in shares due to auto concerns provides an attractive entry point. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/05/18
BMOC
03/05/18
INITIATION
Target $249
BMOC
Market Perform
Becton Dickinson initiated with a Market Perform at BMO Capital
BMO Capital analyst Joanne Wuensch initiated Becton Dickinson with a Market Perform rating and a $249.00 price target.
LH LabCorp
$187.71

-1.23 (-0.65%)

06/07/18
KEYB
06/07/18
UPGRADE
KEYB
Overweight
LabCorp upgraded to Overweight from Sector Weight at KeyBanc
06/07/18
06/07/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Darden (DRI) upgraded to Buy from Hold at SunTrust with Jake Bartlett citing his view that its multiple will expand with modest comp sales outperformance beyond fiscal 2018, accelerating unit growth, resumed acquisitions and a higher dividend. 2. Wingstop (WING) upgraded to Outperform from Neutral at Wedbush with analyst Nick Setyan saying he believes drivers of same store sales growth and margin upside relative to current consensus 2018 and 2019 estimates exist. 3. LabCorp (LH) upgraded to Overweight from Sector Weight at KeyBanc with analyst Donald Hooker saying he sees LabCorp and Quest Diagnostics (DGX) benefiting over time from their recent contracts with United Healthcare (UNH) and Aetna (AET). 4. Carrizo Oil & Gas (CRZO) upgraded to Buy from Hold at Tudor Pickering. 5. Canadian Solar (CSIQ) upgraded to Neutral from Underweight at JPMorgan with analyst Paul Coster saying risks from China's new solar policy appear priced in the shares at current levels. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
GSK GlaxoSmithKline
$41.15

-0.065 (-0.16%)

04/25/18
WELS
04/25/18
NO CHANGE
WELS
Market Perform
Glaxo comments on Advair have negative read through for Mylan, says Wells Fargo
Noting that GlaxoSmithKline (GSK) said it now expects branded Advair sales to decline 30% this year, even excluding the impact of a generic, Wells Fargo analyst David Maris said the news has a negative read through for Mylan (MYL) given that its generic Advair is one of the company's highest profile pipeline items. While Advair will be a good generic opportunity, it represents "a fraction of what some might have previously believed," said Maris, who has a Market Perform rating on Mylan shares.
05/16/18
SPHN
05/16/18
INITIATION
Target $16
SPHN
Overweight
Codexis initiated with an Overweight at Stephens
Stephens analyst Drew Jones started Codexis (CDXS) with an Overweight rating and $16 price target, stating that the company's CodeEvolver platform technology has been sought by pharma partners Merck (MRK), GlaxoSmithKline (GSK) and Nestle (NSRGY) and he expects continued deeper adoption from other major industry players.
04/04/18
04/04/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Transocean (RIG) upgraded to Buy from Hold at HSBC. 2. GlaxoSmithKline (GSK) upgraded to Outperform from Neutral at Exane BNP Paribas. 3. BHP Billiton (BHP) upgraded to Sector Perform from Underperform at RBC Capital and to Buy from Neutral at Citi. 4. Boston Beer (SAM) upgraded to Market Perform from Underperform at Cowen with analyst Vivien Azer citing strong Nielsen data in the non-beer category. 5. EnLink Midstream Partners (ENLK) upgraded to Overweight from Neutral at JPMorgan with analyst Jeremy Tonet saying he reduced his distribution growth expectations given the elevated cost of equity, but views the current 11.5% yield as sustainable. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
JNJ Johnson & Johnson
$122.65

0.11 (0.09%)

06/12/18
FBCO
06/12/18
NO CHANGE
Target $151
FBCO
Outperform
Credit Suisse would be surprised to see J&J bid for Boston Scientific
Credit Suisse analyst Vamil Divan would be surprised to see Johnson & Johnson (JNJ) bid for Boston Scientific (BSX), following a report that Stryker (SYK) had approached Boston about a possible acquisition. In general, the analyst believes Johnson & Johnson prefers smaller, targeted acquisitions to larger deals and prefers to obtain technology at an earlier stage before the market has assigned proper value to it. Divan reiterates an Outperform rating and $151 price target on Johnson & Johnson shares.
06/05/18
CANT
06/05/18
NO CHANGE
Target $510
CANT
Overweight
Medtronic robot delay 'clear positive' for Intuitive Surgical, says Cantor
Medtronic (MDT) today at its analyst meeting said it expects commercial launch of its surgical robot in fiscal 2020, which is roughly a year delay compared to the company's prior expectations, Cantor Fitzgerald analyst Craig Bijou tells investors in a research note partially titled "ISRG's Headstart Gets Bigger." The analyst views the revised timing of the commercial launch of Medtronic's robot as a "clear positive" for Intuitive Surgical (ISRG). With the commercial launches of the Medtronic and Johnson & Johnson (JNJ) robots at least 18 months away, Intuitive should continue to grow its global installed base, further advancing its global surgical robotics leadership position, Bijou writes. He reiterates his Overweight rating on the shares with a $510 price target. The stock in afternoon trading is up $8.46 to $486.39.
06/06/18
JEFF
06/06/18
NO CHANGE
Target $49
JEFF
Buy
Pacira sales inflection may 'finally be underway,' says Jefferies
After hosting an investor dinner with Pacira Pharmaceuticals (PCRX) CEO Dave Stack, Jefferies analyst David Steinberg believes a "meaningful sales inflection for Exparel may finally be underway." Management is increasingly confident that an Exparel sales inflection, driven by the Johnson & Johnson (JNJ) partnership and expanded nerve block indication, is underway, Steinberg tells investors in a research note. Further, he believes a "potentially significant" Exparel rest-of-work partnership is likely to be announced prior to the end of 2018. The analyst keeps a Buy rating on Pacira Pharmaceuticals with a $49 price target.
DGX Quest Diagnostics
$110.63

-0.37 (-0.33%)

06/08/18
WBLR
06/08/18
UPGRADE
WBLR
Outperform
Quest Diagnostics upgraded to Outperform from Market Perform at William Blair
William Blair analyst Amanda Murphy upgraded Quest Diagnostics to Outperform.
06/08/18
06/08/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. ConocoPhillips (COP) upgraded to Outperform from Market Perform at Bernstein with analyst Bob Brackett saying the company's "stalwart global portfolio" and Brent pricing helps insulate it from Permian congestion impacting other E&Ps. 2. DexCom (DXCM) upgraded to Overweight from Neutral at JPMorgan with analyst Robbie Marcus saying glucose measurement is becoming an essential tool for patients and DexCom, with the launch of the G6, is the "clear market leader" from a technological standpoint. 3. Penn National (PENN) reinstated with an Overweight from Neutral at JPMorgan with analyst Joseph Gref saying he sees a favorable setup for the shares given an "attractive regional gaming landscape" and the company's margin improvement initiatives. 4. Marathon Oil (MRO) upgraded to Buy from Hold at Tudor Pickering. 5. Quest Diagnostics (DGX) upgraded to Outperform from Market Perform at William Blair with analyst Amanda Murphy citing the recent UnitedHealthcare (UNH) contract change and positive secular trends for larger labs. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
MMM 3M
$204.89

-0.04 (-0.02%)

05/16/18
05/16/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. 3M (MMM) downgraded to Hold from Buy at Jefferies with analyst Laurence Alexander saying he sees less room for multiple expansion in a rising interest rate environment and feels the risk/reward "looks increasingly challenging at this point." 2. Vipshop (VIPS) downgraded to Sector Weight from Overweight at KeyBanc with analyst Hans Chung saying he sees uncertainties around Tencent (TCEHY) and JD.com (JD) contributions ahead, which drove high expectations for the top-line growth and multiple expansion, and sees margin pressure likely to continue driven by sector competition and the company's hike in marketing expenses to grow new customer organically. 3. PPG (PPG) downgraded to Hold from Buy at Jefferies with analyst Laurence Alexander saying persistent concerns over pricing lagging higher oil-derived raw material costs, end market risk and the reliance on buybacks to protect earnings growth could "easily" move PPG's relative multiple to 10%-15% below the market over the next two years. 4. BT Group (BT) downgraded to Market Perform from Outperform at Bernstein. 5. F5 Networks (FFIV) downgraded to Neutral from Buy at DA Davidson with analyst Mark Kelleher saying the positive factors working in the company's favor, such as its ongoing new iSeries product cycle, high gross margins, strong cash flows, and the application of it security solutions have become increasingly more evident after its last earnings report and have since been reflected in the valuation on the stock. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/08/18
SBSH
06/08/18
NO CHANGE
Target $263
SBSH
Buy
3M growth should 'register solidly' within guidance, says Citi
In a research note titled "Brite Days Ahead for 3M," Citi analyst Andrew Kaplowitz says 3M remains the same company that earlier in the year hit relative valuation highs on the strength of its core brands and innovation. Further, management's business transformation efforts continue to improve the company, Kaplowitz writes. He is confident that 3M's core growth should "register solidly" within the company's 3%-4% 2018 guidance despite more difficult second half comparisons. He keeps a Buy rating on the shares with a $263 price target.
05/16/18
JEFF
05/16/18
DOWNGRADE
Target $220
JEFF
Hold
3M downgraded to Hold from Buy at Jefferies
Jefferies analyst Laurence Alexander downgraded 3M to Hold and lowered his price target for the shares to $220 from $250. The analyst sees less room for multiple expansion in a rising interest rate environment and feels the risk/reward "looks increasingly challenging at this point."
05/07/18
WBLR
05/07/18
NO CHANGE
WBLR
Outperform
William Blair says new competition does not change outlook on Align
There were a number of new product introductions this weekend at the American Association of Orthodontists Conference that will compete with Align Technology's (ALGN) Invisalign, William Blair analyst John Kreger tells investors in a research note. These include products from 3M (MMM) and Henry Schein (HSIC), as well as Dentsply Sirona's (XRAY) SureSmile offering, the analyst adds. He views the product offerings as largely in line with expectations, noting that his fundamental outlook on Align has not changed. Investors were well aware of looming competition, specifically from 3M, and the capabilities of the products introduced at the show were largely in line with expectations, Kreger contends. He continues to expect that clear aligners will take share from wires and brackets and maintains an Outperform rating on Align Technology.
AMGN Amgen
$183.64

-1.47 (-0.79%)

06/05/18
JEFF
06/05/18
NO CHANGE
Target $200
JEFF
Buy
Jefferies thesis on Amgen unchanged after Mylan biosimilar approval
Jefferies analyst Michael Yee says the approval of Mylan's (MYL) Neulasta biosimilar is a headline risk factor for Amgen (AMGN) but does not change his thesis on the latter as consensus already knew a biosimilar was coming. The Street models some Neulasta decline already and Amgen's multi-year low price-to-earnings multiple reflects some of this, Yee tells investors in a research note. He keeps a Buy rating on Amgen shares with a $200 price target.
06/12/18
LEER
06/12/18
NO CHANGE
LEER
Too early to see Allergan's atogepant threatening injectables, says Leerink
Leerink analyst Geoffrey Porges notes that Allergan (AGN) announced positive topline data from a phase IIb/III trial of oral CGRP receptor antagonist atogepant in episodic migraine prevention. The analyst believes this data is certainly positive for Allergan and suggests they may eventually have an oral CGRP medicine approval for both acute and preventative treatment of migraines, However, Porges awaits further data disclosure and larger patient numbers to be convinced about comparing the efficacy of atogepant to the more advanced injectable CGRP medicines in development. With regard to Amgen (AMGN) and Alder (ALDR), who both have injectable CGRP antibodies for migraine prevention, potential competitive erosion from orals is still several years away and he continues to see the more severe chronic migraine population as being a more meaningful commercial opportunity for this class.
06/05/18
MSCO
06/05/18
NO CHANGE
Target $50
MSCO
Overweight
Neulasta biosimilar could 'reignite' Mylan momentum, says Morgan Stanley
Morgan Stanley analyst David Risinger said FDA approval of Fulphila, Mylan's (MYL) biosimilar to Amgen's (AMGN) Neulasta, should be a "substantial and durable" profit opportunity and could "reignite" Mylan's upward momentum. He notes that Mylan anticipates launching Fulphila in the coming weeks and that the FDA biosimilar user fee act action date for Coherus' (CHRS) Neulasta biosimilar is November 3. Risinger has an Overweight rating and $50 price target on Mylan shares.
MCK McKesson
$149.42

3.85 (2.64%)

05/29/18
LEER
05/29/18
NO CHANGE
Target $160
LEER
Market Perform
McKesson price target lowered to $160 from $170 at Leerink
Leerink analyst David Larsen lowered his price target for McKesson to $160 from $170 saying he is slightly more cautious on the company and the drug distribution group following its earnings report and call. Continued commentary of stabilizing drug pricing trends bodes well for the group, but the analyst is still worry about renewals, generic pricing pressure, and a slowdown in list price inflation. Larsen reiterates a Market Perform rating on the shares.
02/27/18
BOFA
02/27/18
INITIATION
Target $179
BOFA
McKesson reinstated with a Buy at BofA/Merrill
BofA/Merrill analyst Michael Cherny reinstated coverage on McKesson with a Buy and $179 price target.
03/08/18
LEHM
03/08/18
INITIATION
Target $165
LEHM
Equal Weight
McKesson initiated with an Equal Weight at Barclays
Barclays analyst Steve Valiquette started McKesson with an Equal Weight rating and $165 price target. The analyst initiated 14 companies in Health Care Services with a Neutral industry view.
04/17/18
MZHO
04/17/18
NO CHANGE
MZHO
Amazon news removes 'unprecedented overhang' on drug sellers, says Mizuho
After CNBC reported yesterday afternoon that Amazon (AMZN) has decided to shelve its plan to sell and distribute pharmaceutical products, Mizuho analyst Ann Hynes said she had thought Amazon's current logistics and distribution model would not translate into healthcare. However, based on conversations with investors, she believes the magnitude of the overhang that Amazon presented for drug distributors and retail pharmacies was "unprecedented." While drug pricing is still a concern, she notes that the CNBC report removes one overhang on the drug supply chain stocks. Hynes remain a buyer of CVS Health (CVS) and Walgreens (WBA) and keeps Neutral ratings on Rite Aid (RAD) as well as on drug distributors AmerisourceBergen (ABC), Cardinal Health (CAH) and McKesson (MCK).
BAX Baxter
$74.57

-0.825 (-1.09%)

05/17/18
05/17/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Costco (COST) initiated with a Buy at Loop Capital. 2. Align Technology (ALGN) initiated with an Outperform at Evercore ISI. 3. Baxter (BAX) assumed with an Overweight at Piper Jaffray. 4. Comtech (CMTL) initiated with a Neutral at Citi. 5. Helius Medical (HSDT) initiated with a Buy at BTIG. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/22/18
PIPR
05/22/18
NO CHANGE
Target $77
PIPR
Overweight
Baxter buybacks should push shares higher, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien says the long-term guidance Baxter announced yesterday at its analyst meeting is essentially in-line with expectations. The key takeaways are the innovation Baxter is delivering, with $1.7B in new products expected over the next five years, and its "sizable" free cash flow, O'Brien tells investors in a research note. The cash flow will allow the company to execute accretive deals or share repurchases, conceivably as much as 20% of outstanding stock, the analyst adds. He believes this could push shares higher in the coming quarters and keeps an Overweight rating on Baxter with a $77 price target. O'Brien encourages investors to start or build positions in the name.
05/17/18
PIPR
05/17/18
INITIATION
Target $77
PIPR
Overweight
Baxter assumed with an Overweight at Piper Jaffray
Piper Jaffray analyst Matt O'Brien assumed coverage of Baxter International with an Overweight rating and $77 price target. Management has done an "excellent job" in quickly turning the company around, O'Brien tells investors in a research note. He believes there is further gross margin expansion available to push earnings higher and that the company's "clean" balance sheet should provide opportunity to do an accretive deal.
05/14/18
ARGS
05/14/18
NO CHANGE
ARGS
Hold
Baxter pullback would warrant a potential upgrade, says Argus
Argus analyst John Eade kept his Hold rating on Baxter after the company's Q1 earnings beat and raised FY18 outlook, saying he would consider an upgrade if the stock price pulled back to the mid-$60's range. The analyst notes that Baxter has "substantially improved profitability in recent quarters" even as it continues to rely on M&A as a source of revenue and margin growth. Eade adds that while the company's Renal and Hospital Products segments are mature businesses, the company's balance sheet is clean, and the management's recent dividend raise is indicative of its confidence in Baxter's prospects.
XRAY Dentsply Sirona
$44.50

0.31 (0.70%)

05/16/18
DBAB
05/16/18
NO CHANGE
Target $55
DBAB
Buy
Dentsply Sirona price target lowered to $55 from $76 at Deutsche Bank
Deutsche Bank analyst Glen Santangelo lowered his price target for Dentsply Sirona to $55 following the company's Q1 results. The analyst revised his estimates to reflect the company's heightened investments, slightly lower revenue growth due to challenges in U.S. technology and equipment, and dilution from the recent OraMetrix acquisition. Despite the "disappointing" reduction in fiscal 2018 guidance, Dentsply's set-up for next year is encouraging as the company reaps some of the benefits from its investments, Santangelo tells investors in a research note. He keeps a Buy rating on the shares.
06/05/18
06/05/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Ulta Beauty (ULTA) downgraded to Neutral from Buy at Goldman Sachs with analyst Matthew Fassler saying shares have recently recovered, but sales momentum continues to moderate following a deceleration for six consecutive quarters in same-store-sales. 2. Take-Two (TTWO) downgraded to Market Perform from Outperform at BMO Capital with analyst Gerrick Johnson saying he is "concerned" expectations for the Red Dead Redemption 2 release could be overly optimistic and sees a risk to earnings from a potential slowdown in Grand Theft Auto and NBA 2K. 3. Loxo Oncology (LOXO) downgraded to Market Perform from Strong Buy at IFS Securities. 4. Dentsply Sirona (XRAY) downgraded to Neutral from Buy at Northcoast. 5. First Solar (FSLR) downgraded to Neutral from Buy at BofA/Merrill with analyst Julien Dumoulin-Smith saying she expects a "steep" drop in 2018 Chinese solar deployments following China's recent 2018 Solar PV Power Generation Notice, with further declines in 2019/2020 possible. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/08/18
BRRR
05/08/18
NO CHANGE
Target $54
BRRR
Outperform
Dentsply Sirona price target lowered to $54 from $70 at Barrington
Barrington analyst Michael Petusky lowered his price target for Dentsply Sirona to $54 citing the "disappointing" earnings guidance for 2018. The lower profitability outlook is related to a slightly lower revenue outlook for 2018, increased internal investment, and the costs associated with the recent OraMetrix transaction, Petusky tells investors in a research note. He keeps an Outperform rating on Dentsply Sirona.
06/05/18
NRCS
06/05/18
DOWNGRADE
NRCS
Neutral
Dentsply Sirona downgraded to Neutral from Buy at Northcoast

TODAY'S FREE FLY STORIES

ENIA

Enel Americas

$9.25

-0.08 (-0.86%)

19:01
06/17/18
06/17
19:01
06/17/18
19:01
Upgrade
Enel Americas rating change at Goldman Sachs »

Enel Americas upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UL

Unilever; also tag UN

$54.26

0.64 (1.19%)

, UN

Unilever; also tag UL

$54.74

0.7 (1.30%)

18:55
06/17/18
06/17
18:55
06/17/18
18:55
Periodicals
Unilever taking stand against digital media's fake followers, Reuters says »

Unilever, the…

UL

Unilever; also tag UN

$54.26

0.64 (1.19%)

UN

Unilever; also tag UL

$54.74

0.7 (1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWX

Time Warner

$98.91

(0.00%)

, CMCSA

Comcast

$33.85

0.03 (0.09%)

16:58
06/17/18
06/17
16:58
06/17/18
16:58
Hot Stocks
Box Office Battle: 'Incredibles 2' breaks record with $180M »

Disney (DIS) and…

TWX

Time Warner

$98.91

(0.00%)

CMCSA

Comcast

$33.85

0.03 (0.09%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$49.11

-0.02 (-0.04%)

FOX

21st Century Fox

$44.57

0.14 (0.32%)

FOXA

21st Century Fox

$44.60

0.03 (0.07%)

LGF.A

Lionsgate

$26.57

1.52 (6.07%)

DIS

Disney

$108.91

0.15 (0.14%)

VIAB

Viacom

$29.40

0.49 (1.69%)

VIA

Viacom

$33.95

0.15 (0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 19

    Jun

OAS

Oasis Petroleum

$12.01

-0.63 (-4.98%)

, OMP

Oasis Midstream Partners

$17.29

-1.02 (-5.57%)

16:46
06/17/18
06/17
16:46
06/17/18
16:46
Conference/Events
JPMorgan to hold a conference »

3rd Annual Energy Equity…

OAS

Oasis Petroleum

$12.01

-0.63 (-4.98%)

OMP

Oasis Midstream Partners

$17.29

-1.02 (-5.57%)

SRCE

1st Source

$55.36

0.13 (0.24%)

LGCY

Legacy Reserves

$6.07

-0.03 (-0.49%)

EVA

Enviva

$29.35

0.15 (0.51%)

CRC

California Resources

$35.03

-2.57 (-6.84%)

INSM

Insmed

$26.74

-1.5 (-5.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 28

    Sep

16:43
06/17/18
06/17
16:43
06/17/18
16:43
Conference/Events
Leerink to hold a tour »

Ribs N' Bones Bus…

16:40
06/17/18
06/17
16:40
06/17/18
16:40
Conference/Events
Citigroup to hold a conference »

2018 European Healthcare…

GM

General Motors

$43.91

0.32 (0.73%)

, FCAU

Fiat Chrysler

$20.86

-0.37 (-1.74%)

16:38
06/17/18
06/17
16:38
06/17/18
16:38
Periodicals
Automakers putting smaller engines into big trucks, WSJ reportsFord »

U.S. auto makers are…

GM

General Motors

$43.91

0.32 (0.73%)

FCAU

Fiat Chrysler

$20.86

-0.37 (-1.74%)

F

Ford

$11.88

-0.01 (-0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

MSFT

Microsoft

$100.24

-1.14 (-1.12%)

, GOOGL

Alphabet Class A

$1,159.03

-1.08 (-0.09%)

16:34
06/17/18
06/17
16:34
06/17/18
16:34
Periodicals
Microsoft is fixing office, WSJ reports »

The new version of…

MSFT

Microsoft

$100.24

-1.14 (-1.12%)

GOOGL

Alphabet Class A

$1,159.03

-1.08 (-0.09%)

GOOG

Alphabet

$1,151.95

-0.05 (-0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 28

    Oct

16:34
06/17/18
06/17
16:34
06/17/18
16:34
Conference/Events
Deutsche Bank to hold a conference »

Taiwan Auto Electronics…

WFC

Wells Fargo

$54.99

0.23 (0.42%)

, MS

Morgan Stanley

$51.17

-0.12 (-0.23%)

16:33
06/17/18
06/17
16:33
06/17/18
16:33
Conference/Events
Federal Reserve Bank of New York to hold a conference »

Reforming Culture &…

WFC

Wells Fargo

$54.99

0.23 (0.42%)

MS

Morgan Stanley

$51.17

-0.12 (-0.23%)

BAC

Bank of America

$29.27

-0.24 (-0.81%)

C

Citi

$66.34

0.18 (0.27%)

WBK

Westpac Banking

$20.67

0.125 (0.61%)

GS

Goldman Sachs

$232.00

-1.695 (-0.73%)

BCS

Barclays

$10.59

-0.225 (-2.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 19

    Jun

  • 19

    Jun

  • 21

    Jun

  • 22

    Jun

  • 13

    Jul

  • 10

    Sep

  • 14

    Jan

  • 12

    Apr

  • 15

    Apr

  • 13

    Jul

  • 16

    Jul

  • 15

    Oct

  • 15

    Oct

F

Ford

$11.88

-0.01 (-0.08%)

16:25
06/17/18
06/17
16:25
06/17/18
16:25
Hot Stocks
Ford acquires Michigan Central Station »

Ford Motor has acquired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY

Bristol-Myers

$54.81

1.165 (2.17%)

16:22
06/17/18
06/17
16:22
06/17/18
16:22
Hot Stocks
Bristol-Myers' ELOQUENT-3 trial meets primary endpoint »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 10

    Jul

PTCT

PTC Therapeutics

$37.57

-0.75 (-1.96%)

, RHHBY

Roche

$0.00

(0.00%)

16:18
06/17/18
06/17
16:18
06/17/18
16:18
Hot Stocks
PTC Therapeutics presents updated preliminary data from SMA FIREFISH Program »

PTC Therapeutics (PTCT)…

PTCT

PTC Therapeutics

$37.57

-0.75 (-1.96%)

RHHBY

Roche

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYTK

Cytokinetics

$9.95

0.5 (5.29%)

16:15
06/17/18
06/17
16:15
06/17/18
16:15
Hot Stocks
Cytokinetics announces data from Phase 2 clinical study of Reldesemtiv in SMA »

Cytokinetics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PERY

Perry Ellis

$27.92

0.31 (1.12%)

16:12
06/17/18
06/17
16:12
06/17/18
16:12
Hot Stocks
Perry Ellis enters into $437M transaction to become private company »

Perry Ellis International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VSTM

Verastem

$6.53

0.95 (17.03%)

16:08
06/17/18
06/17
16:08
06/17/18
16:08
Hot Stocks
Verastem presents duvelisib data at EHA 2018 annual meeting »

Verastem announced one…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Oct

IQ

iQIYI

$40.16

-0.44 (-1.08%)

16:05
06/17/18
06/17
16:05
06/17/18
16:05
Hot Stocks
iQIYI obtains broadcasting rights for all four golf majors »

iQIYI announced it had…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HD

Home Depot

$200.55

0.86 (0.43%)

15:56
06/17/18
06/17
15:56
06/17/18
15:56
Conference/Events
Home Depot participates in a field trip with UBS »

Field Trip to Atlanta, GA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAY

Verifone

$22.84

0.01 (0.04%)

15:28
06/17/18
06/17
15:28
06/17/18
15:28
Conference/Events
Verifone to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CACI

CACI

$167.60

1.1 (0.66%)

14:18
06/17/18
06/17
14:18
06/17/18
14:18
Conference/Events
CACI to hold a webcast »

Management discusses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jun

ARGX

Argenx

$92.38

-3.32 (-3.47%)

14:11
06/17/18
06/17
14:11
06/17/18
14:11
Conference/Events
Argenx to hold a KOL breakfast symposium »

Management holds a Key…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

PTC

PTC

$94.87

-0.46 (-0.48%)

14:06
06/17/18
06/17
14:06
06/17/18
14:06
Conference/Events
PTC to host analyst day »

Analyst Day to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:41
06/17/18
06/17
13:41
06/17/18
13:41
Conference/Events
Federal Reserve Bank of Atlanta president speaks at a meeting »

Atlanta Federal Reserve…

VRX

Valeant

$26.86

0.06 (0.22%)

13:31
06/17/18
06/17
13:31
06/17/18
13:31
Conference/Events
Breaking Conference/Events news story on Valeant »

FDA PDUFA Date for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 27

    Aug

WMGI

Wright Medical

$25.83

-0.26 (-1.00%)

13:27
06/17/18
06/17
13:27
06/17/18
13:27
Conference/Events
Wright Medical management to meet with Leerink »

Meeting to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 19

    Jun

  • 20

    Jun

  • 25

    Jun

  • 26

    Jun

  • 12

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.